Physician profile
Mohan Amlani
NPI 1720068968
$6,101.83
in general payments reported to CMS, 2019-2025
15 companies · $710 in 2025
The $710 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $623 · 2020: $589 · 2021: $1,487 · 2022: $904 · 2023: $1,038 · 2024: $752 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,499.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,185.95 | 2019-2025 | Sunlenca, Biktarvy |
| Viiv Healthcare Company | $1,763.73 | 2019-2025 | Cabenuva, Dovato |
| Insmed, INC. | $543.96 | 2019-2025 | Arikayce, Brinsupri |
| Janssen Biotech, INC. | $542.90 | 2020-2023 | Symtuza |
| Janssen Products, LP | $232.37 | 2021 | |
| Abbvie INC. | $183.60 | 2022-2025 | Avycaz, Dalvance |
| Shionogi INC | $163.06 | 2023-2024 | Fetroja |
| Merck Sharp & Dohme LLC | $140.43 | 2019-2025 | Pifeltro, Zerbaxa, Delstrigo |
| Paratek Pharmaceuticals, INC. | $138.56 | 2019-2022 | |
| La Jolla Pharmaceutical Company | $57.67 | 2021-2022 | |
| Tetraphase Pharmaceuticals, INC. | $56.50 | 2020 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2022 | |
| Janssen Scientific Affairs, LLC | $26.92 | 2021 | |
| Bioxcel Therapeutics, INC. | $22.64 | 2023 | Igalmi |
| Pfizer INC. | $15.06 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohan Amlani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.